SHROOM2

Across TCGA pan-cancer cohorts, SHROOM2 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated SHROOM2 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher SHROOM2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SHROOM2 expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

READ, BRCA, and UCEC are the cancer types where SHROOM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.111	0.919	<.001	29	view →
BRCA	OS	Median	III,IV	0.001	0.907	<.001	16	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
SARC	DFS	Median	All	0.063	0.640	<.001	6	view →
SKCM	DFS	Median	IV	0.016	0.454	<.001	6	view →
COAD	OS	Median	All	0.302	0.706	.031	4	view →
LGG	DFS	Median	All	0.216	0.728	.022	3	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →
ESCA	OS	Median	III,IV	1.000	0.519	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

SHROOM2–READ (OS)

Open the READ breakdown →